• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 7.3Dopamine plus levodopa compared with levodopa monotherapy (1+)

OutcomeSignificance
Clinical rating scales
UPDRS totalNS157
UPDRS II (activities of daily living)NS151,160
Li/LD159
UPDRS III (motor)Li/LD159,161, BR/LD161
UPDRS IVNS159,161
UPDRS addendum (motor complications) scoresLi/LD159
On time during dayNS161
Hoehn and YahrNS154,159,160,162
LD161
Webster scoreNS154
BR/LD161
Columbia University Rating Scale (CURS)BR/LD161
Modified CURSNS151
Schwab and England scoreLi/LD159
NUDSLD161
Adverse events
All eventsNS151,154
MortalityBR/LD115
Nausea/vomitingLD161
Fatigue/weaknessLD161
Hallucinations/confusionLD161
Withdrawal rates
Number of drop-outsNS151,154,157
Li/LD159

LD = levodopa; Li = lisuride; BR = bromocriptine; LD = in favour (p<0.05) of levodopa monotherapy; Li or BR/LD = in favour of (p<0.05) combination therapy; NS = non-significant.

From: 7, Symptomatic pharmacological therapy in Parkinson’s disease

Cover of Parkinson's Disease
Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care.
NICE Clinical Guidelines, No. 35.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2006, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.